Contents
On November 10, the European Commission approved an agreement to purchase COVID-19 vaccines, produced by the pharmaceutical company Valneva. The contract provides for the possibility of purchasing almost 27 million doses by all EU countries in 2022. The preparation differs from the vaccines against coronavirus known to us. What exactly?
Access to a new potential COVID-19 vaccine
Soon, Europeans will be able to vaccinate themselves with Valneva’s new preparation – VLA2001, the first inactivated COVID-19 vaccine. On November 10, the European Commission approved an agreement for the possibility of purchasing up to 60 million doses of the new preparation by EU members (27 million doses in 2022 and up to 33 million additional vaccines in 2023). The next step will be to test the vaccine by the European Medicines Agency to confirm its effectiveness and safety.
– I would like to thank the relevant teams in the EC and the entire Valneva who worked hard on this contract. We are looking forward to starting the process of testing our preparation by the European Medicines Agency. Our latest data from the third phase of clinical trials allowed us to demonstrate the value of our preparation – said Valneva Business Director Franck Grimaud.
“Guarantee that Europe will be well prepared for immunization”
The Valneva vaccine is already the eighth preparation in the “arsenal” of the European Commission. “This diverse set of vaccines will ensure that Europe is well prepared for vaccination as soon as vaccines are safe and effective,” reads the European Commission communication.
The President of the European Commission, Ursula von der Leyen, was very pleased with the completed negotiations and emphasized the role of vaccines in the fight against the current global pandemic.
Do you want to test your COVID-19 immunity after vaccination? Have you been infected and want to check your antibody levels? See the COVID-19 immunity test package, which you will perform at Diagnostics network points.
The continuing COVID-19 pandemic in Europe and around the world makes it more important than ever that all Member States have access to the widest possible range of vaccines to help protect people in Europe and beyond. Today’s step towards reaching an agreement with Valneva completes the vaccine lineup and demonstrates the commission’s commitment to finding a lasting solution to the pandemic, Ursula von der Leyen said.
Valneva COVID-19 vaccine – how does it work?
The formulation developed by the pharmaceutical company Valneva is the only COVID-19 vaccine containing all (killed) virus. It is an inactivated preparation – which is more traditional than mRNA vaccines. Similar technology is used in Chinese vaccines from Sinopharm and Sinovac. «It is a traditional vaccination technology, used for 60-70 years, with a well-established methodology and a high level of safety. It is currently the only potential vaccine containing an inactivated virus in clinical trials against COVID-19 in Europe »- reported the European Commission in a press release.
- Types of COVID-19 Vaccines. How is vector different from mRNA vaccine? [WE EXPLAIN]
Source: Valneva, European Commission / PAP
You may be interested in:
- Will a fourth dose of COVID-19 vaccine be needed? What is known about this topic?
- How long does the third dose protect? Israeli research results leaked
- The third dose of the COVID-19 vaccine for people 18+. Five important questions [WE EXPLAIN]
The content of the medTvoiLokony website is intended to improve, not replace, the contact between the Website User and their doctor. The website is intended for informational and educational purposes only. Before following the specialist knowledge, in particular medical advice, contained on our Website, you must consult a doctor. The Administrator does not bear any consequences resulting from the use of information contained on the Website. Do you need a medical consultation or an e-prescription? Go to halodoctor.pl, where you will get online help – quickly, safely and without leaving your home.